DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
IRVINE, Calif., Feb. 17, 2016 -- CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal, miscarriage analysis and postnatal developmental disorders and pre-implantation genetic screening (PGS) services, announces that it has received a letter from the NASDAQ Listing Qualifications Staff notifying the Company that it has regained full compliance with NASDAQ's minimum bid price continued listing requirement.
The letter, received February 16, 2016, noted that the closing bid price of CombiMatrix’s common stock has been at $1.00 per share or higher for the last 10 consecutive business days, from February 1, 2016 to February 12, 2016. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed. There can be no assurance, however, that the Company will be able to maintain compliance with the minimum bid price requirement in the future.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic screening, miscarriage analysis, prenatal and pediatric diagnostics, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.
Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Investor Relations Contact: LHA Jody Cain (310) 691-7100 [email protected]
